Literature DB >> 29312486

Interleukin-25 enhances the capacity of mesenchymal stem cells to induce intestinal epithelial cell regeneration.

Jingling Su1, Chenxi Xie1, Yanyun Fan1, Weizi Cheng1, Yiqun Hu1, Qingwen Huang1, Huaxiu Shi1, Lin Wang1, Jianlin Ren1.   

Abstract

BACKGROUND: This study aimed to investigate the influence of IL-25 on the capacity of mesenchymal stem cells (MSCs) to induce intestinal epithelial cell regeneration.
METHODS: The CD4+IL-25R+ cells and LGR5+IL-25R+ cells in colonic mucosa of Crohn's disease (CD) patients, ulcerative colitis (UC) patients and healthy controls were detected by immunofluorescence staining, and the CD4+IL-25R+ cells in peripheral blood were detected by flow cytometry. Rat MSCs were separated and stimulated with IL-25. Then, MSCs were further incubated in IL-25-free DMEM for 24 h, and this DMEM was collected as conditioned medium (CM). IEC-6 cells were divided into 3 groups: experimental group (CM and TNF-α), control group (DMEM and TNF-α) and negative control group (DMEM).
RESULTS: The CD4+IL-25R+ cells and LGR5+IL-25R+ cells significantly increased in the colonic mucosa of active CD patients and UC patients compared with IBD patients in remission and healthy controls. The CD4+IL-25R+ cells reduced in peripheral blood of IBD patients, which was inversely correlated with inflammatory markers (ESR and CRP). CM facilitated the migration and proliferation of IEC-6 cells in the presence of TNF-α. The protein expression of AKT, p38 and ERK increased in IEC-6 cells after treatment with CM and TNF-α.
CONCLUSION: IL-25R is involved in Th-related mucosal inflammation and proliferation of intestinal stem cells in IBD. IL-25 enhances the capacity of MSC to induce intestinal epithelial cell regeneration, and MSC therapy with IL-25 may be a new direction for IBD treatment.

Entities:  

Keywords:  CD4; Inflammatory bowel disease; interleukin-25; intestinal stem cell; mesenchymal stem cells

Year:  2017        PMID: 29312486      PMCID: PMC5752884     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  39 in total

1.  Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.

Authors:  Marjolijn Duijvestein; Anne Christine W Vos; Helene Roelofs; Manon E Wildenberg; Barbara B Wendrich; Henricus W Verspaget; Engelina M C Kooy-Winkelaar; Frits Koning; Jaap Jan Zwaginga; Herma H Fidder; Auke P Verhaar; Willem E Fibbe; Gijs R van den Brink; Daniel W Hommes
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  Mesenchymal Stromal Cells Mitigate Experimental Colitis via Insulin-like Growth Factor Binding Protein 7-mediated Immunosuppression.

Authors:  Yan Liao; Junxia Lei; Muyun Liu; Wanwen Lin; Dongxi Hong; Ying Tuo; Mei Hua Jiang; Huimin Xia; Maosheng Wang; Weijun Huang; Andy Peng Xiang
Journal:  Mol Ther       Date:  2016-07-09       Impact factor: 11.454

3.  Molecular analysis of interleukin-25 exons 1 and 2 and its serum levels in Iranian patients with multiple sclerosis.

Authors:  Mohammad-Reza Javan; Narges Seyfizadeh; Saeed Aslani; Mehdi Farhoodi; Zohreh Babaloo
Journal:  Am J Clin Exp Immunol       Date:  2014-08-15

Review 4.  Interleukin-25: key regulator of inflammatory and autoimmune diseases.

Authors:  David Saadoun; Benjamin Terrier; Patrice Cacoub
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

Review 5.  Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease.

Authors:  Zbigniew Kmieć; Marta Cyman; Tomasz Jerzy Ślebioda
Journal:  Adv Med Sci       Date:  2017-01-23       Impact factor: 3.287

Review 6.  Interleukin-25: a two-edged sword in the control of immune-inflammatory responses.

Authors:  Giovanni Monteleone; Francesco Pallone; Thomas T Macdonald
Journal:  Cytokine Growth Factor Rev       Date:  2010-06-01       Impact factor: 7.638

Review 7.  Interleukin-25 (or IL-17E): a new IL-17 family member with growth factor/inflammatory actions.

Authors:  D Kempuraj; S Frydas; P Conti; K Kandere- Grzybowska; W Boucher; R Letourneau; B Madhappan; S H Huang; K Sugimoto; N G Papadopoulou; S Christodoulou; T C Theoharides
Journal:  Int J Immunopathol Pharmacol       Date:  2003 Sep-Dec       Impact factor: 3.219

8.  Identification of stem cells in small intestine and colon by marker gene Lgr5.

Authors:  Nick Barker; Johan H van Es; Jeroen Kuipers; Pekka Kujala; Maaike van den Born; Miranda Cozijnsen; Andrea Haegebarth; Jeroen Korving; Harry Begthel; Peter J Peters; Hans Clevers
Journal:  Nature       Date:  2007-10-14       Impact factor: 49.962

9.  Therapeutic effects of mouse bone marrow-derived clonal mesenchymal stem cells in a mouse model of inflammatory bowel disease.

Authors:  Jin Seok Park; Tac-Ghee Yi; Jong-Min Park; Young Min Han; Jun-Hyung Kim; Dong-Hee Shin; Seon Ji Tak; Kyuheon Lee; Youn Sook Lee; Myung-Shin Jeon; Ki-Baik Hahm; Sun U Song; Seok Hee Park
Journal:  J Clin Biochem Nutr       Date:  2015-10-21       Impact factor: 3.114

Review 10.  Inflammatory bowel disease: clinical aspects and treatments.

Authors:  Marc Fakhoury; Rebecca Negrulj; Armin Mooranian; Hani Al-Salami
Journal:  J Inflamm Res       Date:  2014-06-23
View more
  3 in total

Review 1.  Mechanism of Acupuncture and Moxibustion on Promoting Mucosal Healing in Ulcerative Colitis.

Authors:  Han Li; Xiao-Feng Ye; Yang-Shuai Su; Wei He; Jian-Bin Zhang; Qi Zhang; Li-Bin Zhan; Xiang-Hong Jing
Journal:  Chin J Integr Med       Date:  2022-04-12       Impact factor: 1.978

Review 2.  Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease.

Authors:  Meng-Yue Shi; Lian Liu; Fu-Yuan Yang
Journal:  World J Stem Cells       Date:  2022-09-26       Impact factor: 5.247

Review 3.  Type 2 immunity in intestinal homeostasis and inflammatory bowel disease.

Authors:  Xinxin Luo; Eduardo J Villablanca
Journal:  Biochem Soc Trans       Date:  2021-11-01       Impact factor: 5.407

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.